Use of genetic information within clinical drug development primarily depends on effect size and predictive value of the marker(s) to the associated endpoint.
Obviously, various characteristics of nanomaterial could impact associated biochemical endpoints.
In addition to being linked to adiposity traits, the trans eQTL signature is associated with endpoints relevant to diabetes, namely glucose traits (Table 1, Table S2, and Figure S2).
Finally, MARS and WAI score were both associated to endpoint CGI (regression coefficients 0.05 (0.02; 0.08) and −0.01 (−0.01; −0.004), respectively) and endpoint GAF scores (regression coefficients-0.41 (−0.80;-0.01) and (0.10 (0.06; 0.14 respectively).
SUM2 an SUM3 ratings were associated to endpoint GAF score (regression coefficients 1.05 (0.11; 1.99) and 2.49 (1.34; 3.64), respectively) but not to endpoint CGI score (regression coefficients −0.02 (−0.09; 0.06) and −0.06 (−0.15; 0.03), respectively).
For most of the analyses, baseline symptom severity was not significantly associated with endpoint health outcomes.
For Clinical Trials 1 and 2, baseline symptom severity was not associated with endpoint PGWB total scores.
Acamprosate was associated at endpoint analysis with improvements on binge frequency, food craving and quality of life compared to placebo [ 77].
Additionally, an interaction of remission status and most markedly with TPH1 CC genotype was found to be associated with endpoint HA score.
To evaluate whether baseline heartburn severity is associated with endpoint HRQL scores, we focused on the interaction between baseline symptom severity and complete resolution status at follow-up, based on an analysis of covariance (ANCOVA) model.
